Triferic is a drug owned by Rockwell Medical Inc. It is protected by 4 US drug patents filed from 2015 to 2019. Out of these, 2 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 17, 2029. Details of Triferic's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7816404 | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
Apr, 2029
(4 years from now) | Active |
| US7857977 | Packaging of ferric pyrophosphate for dialysis |
Sep, 2027
(2 years from now) | Active |
| US6779468 | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
Dec, 2016
(7 years ago) |
Expired
|
| US6689275 | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
Dec, 2016
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Triferic's patents.
Latest Legal Activities on Triferic's Patents
Given below is the list of recent legal activities going on the following patents of Triferic.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 19 May, 2022 | US7857977 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 22 Mar, 2022 | US7816404 |
| Email Notification Critical | 16 Jan, 2019 | US7816404 |
| Correspondence Address Change Critical | 15 Jan, 2019 | US7816404 |
| Change in Power of Attorney (May Include Associate POA) Critical | 15 Jan, 2019 | US7816404 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 14 Jun, 2018 | US7857977 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Apr, 2018 | US7816404 |
| Change in Power of Attorney (May Include Associate POA) Critical | 17 Jan, 2014 | US7857977 |
| Change in Power of Attorney (May Include Associate POA) Critical | 17 Jan, 2014 | US7816404 |
| Correspondence Address Change Critical | 16 Jan, 2014 | US7857977 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Triferic and ongoing litigations to help you estimate the early arrival of Triferic generic.
Triferic's Litigations
Triferic been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 13, 2009, against patent number US7857977. The petitioner , challenged the validity of this patent, with Lori L. Wash as the respondent. Click below to track the latest information on how companies are challenging Triferic's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7857977 | February, 2009 |
Decision
(23 Aug, 2010) | Lori L. Wash | |
US patents provide insights into the exclusivity only within the United States, but Triferic is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Triferic's family patents as well as insights into ongoing legal events on those patents.
Triferic's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Triferic's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 17, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Triferic Generics:
There are no approved generic versions for Triferic as of now.
Alternative Brands for Triferic
Triferic which is used for treating iron deficiency anemia., has several other brand drugs using the same active ingredient (Ferric Pyrophosphate Citrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Rockwell Medical Inc |
|
About Triferic
Triferic is a drug owned by Rockwell Medical Inc. It is used for treating iron deficiency anemia. Triferic uses Ferric Pyrophosphate Citrate as an active ingredient. Triferic was launched by Rockwell Medical Inc in 2015.
Approval Date:
Triferic was approved by FDA for market use on 23 January, 2015.
Active Ingredient:
Triferic uses Ferric Pyrophosphate Citrate as the active ingredient. Check out other Drugs and Companies using Ferric Pyrophosphate Citrate ingredient
Treatment:
Triferic is used for treating iron deficiency anemia.
Dosage:
Triferic is available in the following dosage forms - solution form for intravenous use, powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 27.2MG IRON/5ML (5.44MG IRON/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| 272MG IRON/PACKET | POWDER | Discontinued | INTRAVENOUS |